All treatments
Treatment
DOXORUBICINE ACCORD 2 mg/ml clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
C5691004 _ A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression
This study is testing a new way to treat a type of cancer called peripheral T-cell lymphoma (PTCL). Researchers want to see if combining a newer drug (brentuximab vedotin) with standard chemotherapy (CHP) works well for people with a specific type of PTCL.
For: Peripheral T-cell LymphomaSpain · Italy · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
This study looks at new ways to treat Hodgkin lymphoma, a type of cancer that affects the immune system. Researchers are testing different combinations of medicines to see how well they work and if they are safe. The main goal is to see if these treatments can make the cancer go away completely.
For: Classical Hodgkin LymphomaSpain · Czechia · Italy